CINECA IRIS Institutional Research Information System

MATRONE, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.881
AS - Asia 5.157
EU - Europa 4.397
SA - Sud America 811
Continente sconosciuto - Info sul continente non disponibili 358
AF - Africa 353
OC - Oceania 11
Totale 20.968
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.572
SG - Singapore 1.712
CN - Cina 1.406
IT - Italia 1.245
DE - Germania 971
HK - Hong Kong 737
BR - Brasile 639
SE - Svezia 616
VN - Vietnam 457
GB - Regno Unito 324
AT - Austria 238
BG - Bulgaria 221
FR - Francia 221
IN - India 182
CA - Canada 175
CI - Costa d'Avorio 165
JP - Giappone 146
RU - Federazione Russa 133
FI - Finlandia 126
TR - Turchia 122
SN - Senegal 75
BD - Bangladesh 69
AR - Argentina 60
MX - Messico 54
PL - Polonia 50
NL - Olanda 46
IQ - Iraq 41
KR - Corea 37
MA - Marocco 36
ZA - Sudafrica 34
PK - Pakistan 32
ID - Indonesia 30
ES - Italia 28
CZ - Repubblica Ceca 26
UA - Ucraina 26
SA - Arabia Saudita 24
VE - Venezuela 24
EC - Ecuador 22
UZ - Uzbekistan 22
CO - Colombia 21
EE - Estonia 20
GR - Grecia 17
AZ - Azerbaigian 16
JM - Giamaica 16
PH - Filippine 16
CH - Svizzera 14
CL - Cile 14
IR - Iran 14
CR - Costa Rica 13
IE - Irlanda 13
LT - Lituania 13
AU - Australia 10
HN - Honduras 10
AE - Emirati Arabi Uniti 9
IL - Israele 9
PE - Perù 9
PY - Paraguay 9
EG - Egitto 8
HU - Ungheria 8
JO - Giordania 8
MY - Malesia 8
TW - Taiwan 8
BE - Belgio 7
GT - Guatemala 7
KE - Kenya 7
LB - Libano 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
DZ - Algeria 6
NP - Nepal 6
PA - Panama 6
TN - Tunisia 6
AL - Albania 5
BO - Bolivia 5
DO - Repubblica Dominicana 5
KZ - Kazakistan 5
MG - Madagascar 5
OM - Oman 5
PS - Palestinian Territory 5
PT - Portogallo 5
TH - Thailandia 5
BH - Bahrain 4
BY - Bielorussia 4
PR - Porto Rico 4
SV - El Salvador 4
CY - Cipro 3
DK - Danimarca 3
ET - Etiopia 3
LV - Lettonia 3
NG - Nigeria 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
EU - Europa 2
GE - Georgia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MC - Monaco 2
MK - Macedonia 2
MM - Myanmar 2
Totale 20.591
Salva come PNG Salva come JPEG
Città #
Ashburn 1.161
Singapore 973
Dallas 969
San Jose 768
Hong Kong 716
Chandler 571
Santa Clara 557
Fairfield 411
Shanghai 313
Milan 302
Beijing 261
New York 261
Houston 252
Los Angeles 227
Woodbridge 223
Sofia 218
Vienna 216
Seattle 176
Munich 175
Council Bluffs 172
Abidjan 165
Boardman 151
Wilmington 148
Ho Chi Minh City 134
Cambridge 133
Princeton 127
Ann Arbor 126
Pisa 126
Tokyo 121
Florence 114
Frankfurt am Main 99
Lauterbourg 98
Lawrence 95
London 90
Hanoi 83
Boulder 82
Dakar 75
Rome 75
Buffalo 73
Serra 71
São Paulo 67
Medford 66
Helsinki 62
Ottawa 61
Istanbul 58
Redondo Beach 55
Atlanta 52
Orem 45
Hefei 43
Dong Ket 42
Turku 42
Des Moines 39
Montreal 36
Bremen 35
Phoenix 35
Redwood City 35
Dearborn 33
San Diego 32
Washington 32
Denver 30
Fuzhou 30
Warsaw 30
Redmond 28
Nanjing 27
Nuremberg 27
Belo Horizonte 26
Seoul 26
Toronto 26
Brooklyn 25
Düsseldorf 25
Chicago 23
Tianjin 23
Casablanca 22
Columbus 22
Haiphong 22
Amsterdam 21
Cascina 21
Lucca 21
Quanzhou 21
Boston 20
Guangzhou 20
Baghdad 19
Tashkent 19
Brno 18
Ogden 18
Stockholm 18
Johannesburg 17
Mumbai 17
Paris 17
Rio de Janeiro 17
San Francisco 17
Ankara 16
Chengdu 16
Mexico City 16
Vicopisano 16
Izmir 15
Poplar 15
Bengaluru 14
Dhaka 14
Dublin 14
Totale 12.827
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 253
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 249
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 248
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 242
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 236
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer 233
Targeted Therapy in Thyroid Cancer: State of the Art 228
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 227
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 225
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 221
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 220
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 216
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 216
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 213
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 203
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 202
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 201
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 200
Il carcinoma tiroideo: nuove prospettive terapeutiche. 199
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 194
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 193
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 192
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 192
Fatal tracheal perforation following Dabrafenib-Trametinib therapy in BRAF V600E-mutant mixed anaplastic thyroid cancer 189
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 189
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 189
18F-DOPA-PET/CT role in medullary thyroid cancer patients with biochemical incomplete response 187
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 186
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 186
Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma 186
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 185
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 183
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 182
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 182
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 181
Risk factors for renal calcifications and determinants of hypercalciuria in patients with chronic, post-surgical hypoparathyroidism 181
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 179
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 178
Impact of energy-based devices in pediatric thyroid surgery 178
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 176
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 175
SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism 175
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses 172
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 171
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 169
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 167
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 167
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 166
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 166
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 164
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 163
Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism 162
Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center 161
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 160
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 160
Increased Risk of Renal Complications in Patients with Chronic Postsurgical Hypoparathyroidism Treated with Conventional Therapy 159
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 158
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 158
Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes 157
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 157
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 157
Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma 154
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 153
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 153
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 153
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 150
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 150
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 149
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 148
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 148
null 146
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 145
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 145
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma 144
Cabozantinib: An orphan drug for thyroid cancer 144
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 143
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 142
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine 142
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 142
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 138
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 138
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 138
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 137
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 136
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 136
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 134
Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience 132
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 131
Un caso di MEN2B con anomalie scheletriche multiple 131
First report of benign track seeding after robot-assisted transaxillary thyroid surgery 130
Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study 129
MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions 129
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 128
La scintigrafia con 99mTecnezio-metossi-isobutil-isonitrile è una metodica utile per caratterizzare il rischio di malignità nei noduli tiroidei a citologia indeterminata 125
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 123
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 123
Obesity as a risk factor for thyroid cancer 122
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 121
Erectile dysfunction in patients treated with selpercatinib for RET altered thyroid cancer 120
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 119
Totale 16.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.171
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.171
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022994 0 0 29 52 208 142 47 42 56 50 74 294
2022/20232.211 239 320 191 166 208 229 44 162 453 17 157 25
2023/20241.476 108 143 199 118 191 273 87 35 26 23 109 164
2024/20254.567 56 157 68 274 480 449 360 216 473 551 463 1.020
2025/20266.772 493 901 789 676 712 434 952 275 427 621 234 258
2026/20271.407 172 918 317 0 0 0 0 0 0 0 0 0
Totale 20.968